Cipla & Formosa Ink Licensing Deal for Clobetasol Suspension Kumar Jeetendra | March 18, 2025 Cipla Limited (BSE: 500087; NSE: CIPLA EQ) referred to as “Cipla” today announced an exclusive licensing agreement with Taiwan-based Formosa Pharmaceuticals (6838.TW) for the commercialization of clobetasol propionate ophthalmic suspension, 0.05% (APP13007). Under this agreement, Cipla has exclusive rights to market the innovative treatment for post-operative inflammation and pain following ocular surgery across 11 countries …
Aurobindo Pharma USA Secures FTC Approval for Lannett Deal Kumar Jeetendra | June 22, 2026 Aurobindo Pharma USA, Inc. a wholly owned subsidiary of the Company, today announced that it has received approval from the U.S. Federal Trade Commission (FTC) to proceed with the acquisition of Lannett Company LLC (“Lannett”). The transaction, valued at $250 million on a cash-free, debt-free basis and inclusive of normalized working capital, is expected to …
